Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded enzyme and transporter findings by polarity

Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.

What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
Public rows
8,404
Generated
Schema version
1.3.0

Coverage

What this run contains

Medicine–counterparty–role groups
8,404
Source sentence records
20,358
Asserted sentences
4,700
Denied sentences
7,494
Polarity not recorded
8,164
Medicines represented
755
Counterparties represented
36
Corpus records considered
9,855
All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
inducer groups
617
inhibitor groups
3,131
not_recorded groups
3,074
substrate groups
1,582

Method

How the rows were made

  1. A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
  2. A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
  3. Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
  4. Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
  5. The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.

Limits

Read these before using a row

  • A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
  • This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
  • ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
  • A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
  • 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
  • Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
  • 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
  • 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
  • The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
  • The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
  • A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
  • Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.

Provenance

Source examples

Abacavir · CYP3A4 inhibitor

2 asserted · 2 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.

Abacavir · BCRP substrate

0 asserted · 4 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.

Abacavir · CYP2C9 not_recorded

0 asserted · 0 denied · 2 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).

Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
medicineNamestringRecorded medicine name; not normalized for display style.
counterpartystringThe exact recorded counterparty spelling.
rolestringSUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role.
assertedCountnumberSentence records whose polarity is ASSERTED.
deniedCountnumberSentence records whose polarity is NEGATED.
polarityNotRecordedCountnumberSentence records for which the parser did not settle assertion or denial.
sentencessentence[]Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact recorded role.

Exact recorded counterparty spelling.

Clear

Showing 1,421–1,430 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 1421

    Medicine slug
    citalopram
    Medicine name
    Citalopram
    Enzyme or transporter
    CYP1A2
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies In vitro enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies In vitro enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19.

  2. Projected row 1422

    Medicine slug
    citalopram
    Medicine name
    Citalopram
    Enzyme or transporter
    CYP1A2
    Role
    SUBSTRATE
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      Theophylline Combined administration of citalopram tablets (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      Theophylline Combined administration of citalopram tablets (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline.

  3. Projected row 1423

    Medicine slug
    citalopram
    Medicine name
    Citalopram
    Enzyme or transporter
    CYP2C19
    Role
    INHIBITOR
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      CYP3A4 and CYP2C19 Inhibitors Since CYP3A4 and CYP2C19 are the primary enzymes involved in the metabolism of citalopram, it is expected that potent inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, and macrolide antibiotics) and inhibitors of CYP2C19 (e.g., omeprazole, cimetidine) might decrease the clearance of citalopram.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      CYP3A4 and CYP2C19 Inhibitors Since CYP3A4 and CYP2C19 are the primary enzymes involved in the metabolism of citalopram, it is expected that potent inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, and macrolide antibiotics) and inhibitors of CYP2C19 (e.g., omeprazole, cimetidine) might decrease the clearance of citalopram.

  4. Projected row 1424

    Medicine slug
    citalopram
    Medicine name
    Citalopram
    Enzyme or transporter
    CYP2C19
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    6
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      In vitro studies using human liver microsomes indicated that CYP3A4 and CYP2C19 are the primary isozymes involved in the N-demethylation of citalopram.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      CYP2C19 Poor Metabolizers In CYP2C19 poor metabolizers, citalopram steady state C max and AUC was increased by 68% and 107%, respectively [see Dosage and Administration (2.3) , Warnings and Precautions (5.2) ] .
    3. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      However, coadministration of citalopram and the potent CYP3A4 inhibitor ketoconazole did not significantly affect the pharmacokinetics of citalopram. 20 mg/day is the maximum recommended citalopram dose in patients taking concomitant cimetidine or another CYP2C19 inhibitor, because of the risk of QT prolongation [see Dosage and Administration (2.2) , Warnings and Precautions (5.2) ] .
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      In vitro studies using human liver microsomes indicated that CYP3A4 and CYP2C19 are the primary isozymes involved in the N-demethylation of citalopram.
    5. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      CYP2C19 Poor Metabolizers In CYP2C19 poor metabolizers, citalopram steady state C max and AUC was increased by 68% and 107%, respectively [see Dosage and Administration (2.3) , Warnings and Precautions (5.2) ] .
    6. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      However, coadministration of citalopram and the potent CYP3A4 inhibitor ketoconazole did not significantly affect the pharmacokinetics of citalopram. 20 mg/day is the maximum recommended citalopram dose in patients taking concomitant cimetidine or another CYP2C19 inhibitor, because of the risk of QT prolongation [see Dosage and Administration (2.2) , Warnings and Precautions (5.2) ] .

  5. Projected row 1425

    Medicine slug
    citalopram
    Medicine name
    Citalopram
    Enzyme or transporter
    CYP2D6
    Role
    INHIBITOR
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      Imipramine and Other Tricyclic Antidepressants (TCAs) In vitro studies suggest that citalopram is a relatively weak inhibitor of CYP2D6.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      Imipramine and Other Tricyclic Antidepressants (TCAs) In vitro studies suggest that citalopram is a relatively weak inhibitor of CYP2D6.

  6. Projected row 1426

    Medicine slug
    citalopram
    Medicine name
    Citalopram
    Enzyme or transporter
    CYP2D6
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    4
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      CYP2D6 Poor Metabolizers Citalopram steady state levels were not significantly different in poor metabolizers and extensive metabolizers of CYP2D6.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      CYP2D6 Inhibitors Coadministration of a drug that inhibits CYP2D6 with citalopram is unlikely to have clinically significant effects on citalopram metabolism, based on the study results in CYP2D6 poor metabolizers.
    3. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      CYP2D6 Poor Metabolizers Citalopram steady state levels were not significantly different in poor metabolizers and extensive metabolizers of CYP2D6.
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      CYP2D6 Inhibitors Coadministration of a drug that inhibits CYP2D6 with citalopram is unlikely to have clinically significant effects on citalopram metabolism, based on the study results in CYP2D6 poor metabolizers.

  7. Projected row 1427

    Medicine slug
    citalopram
    Medicine name
    Citalopram
    Enzyme or transporter
    CYP2D6
    Role
    SUBSTRATE
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      Coadministration of citalopram tablets (40 mg/day for 10 days) with the TCA imipramine (single dose of 100 mg), a substrate for CYP2D6, did not significantly affect the plasma concentrations of imipramine or citalopram.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      Coadministration of citalopram tablets (40 mg/day for 10 days) with the TCA imipramine (single dose of 100 mg), a substrate for CYP2D6, did not significantly affect the plasma concentrations of imipramine or citalopram.

  8. Projected row 1428

    Medicine slug
    citalopram
    Medicine name
    Citalopram
    Enzyme or transporter
    CYP3A4
    Role
    INHIBITOR
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      CYP3A4 and CYP2C19 Inhibitors Since CYP3A4 and CYP2C19 are the primary enzymes involved in the metabolism of citalopram, it is expected that potent inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, and macrolide antibiotics) and inhibitors of CYP2C19 (e.g., omeprazole, cimetidine) might decrease the clearance of citalopram.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      CYP3A4 and CYP2C19 Inhibitors Since CYP3A4 and CYP2C19 are the primary enzymes involved in the metabolism of citalopram, it is expected that potent inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, and macrolide antibiotics) and inhibitors of CYP2C19 (e.g., omeprazole, cimetidine) might decrease the clearance of citalopram.

  9. Projected row 1429

    Medicine slug
    citalopram
    Medicine name
    Citalopram
    Enzyme or transporter
    CYP3A4
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    6
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      In vitro studies using human liver microsomes indicated that CYP3A4 and CYP2C19 are the primary isozymes involved in the N-demethylation of citalopram.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies In vitro enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19.
    3. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      However, coadministration of citalopram and the potent CYP3A4 inhibitor ketoconazole did not significantly affect the pharmacokinetics of citalopram. 20 mg/day is the maximum recommended citalopram dose in patients taking concomitant cimetidine or another CYP2C19 inhibitor, because of the risk of QT prolongation [see Dosage and Administration (2.2) , Warnings and Precautions (5.2) ] .
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      In vitro studies using human liver microsomes indicated that CYP3A4 and CYP2C19 are the primary isozymes involved in the N-demethylation of citalopram.
    5. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies In vitro enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19.
    6. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      However, coadministration of citalopram and the potent CYP3A4 inhibitor ketoconazole did not significantly affect the pharmacokinetics of citalopram. 20 mg/day is the maximum recommended citalopram dose in patients taking concomitant cimetidine or another CYP2C19 inhibitor, because of the risk of QT prolongation [see Dosage and Administration (2.2) , Warnings and Precautions (5.2) ] .

  10. Projected row 1430

    Medicine slug
    citalopram
    Medicine name
    Citalopram
    Enzyme or transporter
    CYP3A4
    Role
    SUBSTRATE
    Asserted sentences
    0
    Denied sentences
    6
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      Warfarin Administration of 40 mg/day citalopram tablets for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate.
    2. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      Carbamazepine Combined administration of citalopram tablets (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.
    3. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      Triazolam Combined administration of citalopram tablets (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.
    4. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      Warfarin Administration of 40 mg/day citalopram tablets for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate.
    5. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      Carbamazepine Combined administration of citalopram tablets (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.
    6. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:0dfb11d9-f48d-56ee-e063-6294a90ad256 (opens source in a new tab)

      Citalopram label

      Version not recorded · Effective date not recorded

      Triazolam Combined administration of citalopram tablets (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=1420

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
role
Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
counterparty
Exact recorded counterparty spelling.
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy